Similar articles

• Trabectedin: new drug. Soft-tissue sarcomas: too many adverse effects.

  [No authors listed] [No authors listed] Prescrire Int. 2009 Aug;18(102):161. Prescrire Int. 2009. PMID: 19743575 No abstract available.
• Optimizing the use of trabectedin for advanced soft tissue sarcoma in daily clinical practice.

  Le Cesne A, Reichardt P. Le Cesne A, et al. Future Oncol. 2015;11(11 Suppl):3-14. doi: 10.2217/fon.15.78. Future Oncol. 2015. PMID: 26043310 Review.
• Trabectedin for the treatment of advanced metastatic soft tissue sarcoma.

  Simpson EL, Rafia R, Stevenson MD, Papaioannou D. Simpson EL, et al. Health Technol Assess. 2010 May;14 Suppl 1:63-7. doi: 10.3310/hta14Suppl1/09. Health Technol Assess. 2010. PMID: 20507805 Review.
• Trabectedin and Eribulin: Where Do They Fit in the Management of Soft Tissue Sarcoma?

  Ratan R, Patel SR. Ratan R, et al. Curr Treat Options Oncol. 2017 Jun;18(6):34. doi: 10.1007/s11864-017-0477-x. Curr Treat Options Oncol. 2017. PMID: 28534249 Review.
• Beyond clinical trials in advanced soft tissue sarcoma: what to expect from trabectedin treatment? Foreword.

  Reichardt P. Reichardt P. Future Oncol. 2015;11(11 Suppl):1. doi: 10.2217/fon.15.77. Future Oncol. 2015. PMID: 26043309 No abstract available.